Last edition
News about
Ajinomoto Bio-Pharma and Olon Forge Partnership to Advance Sustainable Biologics Manufacturing
Ajinomoto Bio-Pharma Services (Aji Bio-Pharma), a global leader in biopharmaceutical contract development and manufacturing, has entered into a strategic partnership with Olon S.p.A. to provide innovative, large-scale drug substance manufacturing solutions for pharmaceutical and biotechnology clients.
Kemwell Biopharma’s drug-product manufacturing facility in Bengaluru has received clearance from the US Food and Drug Administration (FDA) for the commercial manufacturing and testing of injectable products intended for the US market, following the successful completion of a pre-approval inspection (PAI).
Medinet Japan partners with India's Stempeutics for Stempeucel cell therapy to treat CLTI
Medinet Co., Ltd, a Tokyo-listed regenerative medicine and CDMO company, has signed an option licence agreement with India-based Stempeutics Research for the development and commercialisation of its Stempeucel therapy in Japan, targeting Chronic Limb Threatening Ischaemia (CLTI).
Wingcopter and Sincronia Logistica Partner to Deliver Medical Supplies in Mexico with Drones
European drone manufacturer Wingcopter has partnered with Sincronía Logística, a leading Mexican company in pharmaceutical logistics, to promote the use of drones for the delivery of medical supplies across Mexico.
GSK and Empirico Sign Licensing Deal for Respiratory Oligonucleotide
Oligonucleotide therapies, including siRNA, offer the potential to modulate gene expression and target diseases beyond the reach of traditional drugs. EMP-012 adds to GSK’s growing oligonucleotide pipeline across respiratory, immunology and inflammation, and infectious disease portfolios.
Alembic Pharmaceuticals Secures USFDA Approval for Ticagrelor Tablets, 60 mg
Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ticagrelor Tablets, 60 mg. The product is therapeutically equivalent to Brilinta Tablets, 60 mg, from AstraZeneca.
Cambridge Isotope Laboratories (CIL), a subsidiary of Japan’s Otsuka Pharmaceutical, has signed a Memorandum of Understanding (MoU) with Hyderabad-based Chemtatva Chiral Solutions (CCS) to establish a new entity — Cambridge Isotope Laboratories Pvt. Ltd. — in Hyderabad, India.
Cambridge Isotope Laboratories (CIL), a subsidiary of Otsuka Pharmaceutical (Japan), has launched ISOAPI-D, a unified brand of deuterated intermediates for active pharmaceutical ingredient (API) synthesis, at CPhI Frankfurt.
GHIT Fund Announces USD 11.6 Million to Boost R&D for TB, Leishmaniasis and Malaria
The Global Health Innovative Technology (GHIT) Fund, a Japan-based international public-private partnership (PPP), has announced a total investment of approximately USD 11.6 million to support four new research and development (R&D) projects targeting tuberculosis (TB), neglected tropical diseases (NTDs) and malaria.
WINREVAIR from Merck Gains Updated FDA Indication for Pulmonary Arterial Hypertension
Adding WINREVAIR from Merck to background PAH therapy improved exercise capacity and WHO Functional Class (FC), and reduced the risk of clinical worsening events, including hospitalisation for PAH, lung transplantation and death.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy